ArticleFrontiers in medicine2025
Risk factors for virologic failure and persistent low-level viremia in people with HIV experiencing low-level viremia: Chongqing ART cohort study, 2019-2023.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low-level viremia (LLV) during effective antiretroviral therapy (ART) presents ongoing management challenges globally, with reported prevalence rates of 10-46% in resource-limited settings. The clinical significance of LLV remains controversial: while some studies demonstrate that viral load (VL) levels exceeding 200 copies/mL predict virologic failure (VF), others report no significant association. This uncertainty underscores the need for clearer risk stratification in diverse clinical settings. Objective: To investigate risk factors for VF and persistent low-level viremia (pLLV) in HIV-1-infected individuals experiencing LLV. Design: A retrospective cohort study between January 2019 and December 2023, consisting of 1,214 individuals with LLV (defined as plasma HIV-1 RNA levels of 50-999 copies/mL detected at two consecutive time points following previously undetected viral loads) at a large specialized hospital in Chongqing, China. Methods: Clinical data, including demographics, ART regimens, adherence, baseline viral load (VL), CD4 + T-cell counts, and LLV characteristics, were extracted from medical records. Univariate and multivariate logistic regression models were used to identify factors associated with VF (defined as one or more HIV VLs of ≥1,000 copies/mL) and pLLV (defined as at least three consecutive measurements of VL within the range of 50 to 999 copies/mL), with adjustments for potential confounders. Results: Among 1,214 participants with LLV, 2.64% (32/1,214) developed VF, and 28.09% (341/1,214) developed pLLV. Protective factors against VF included baseline VL < 1,000 copies/mL (adjusted odds ratio [aOR] = 0.100, 95%CI: 0.013-0.765) and VL < 200 copies/mL during LLV (aOR = 0.157, 95%CI: 0.071-0.540). Viral blips (transient LLV) independently predicted VF (aOR = 4.6775, 95%CI: 1.392-15.704). For pLLV, baseline VL < 1,000 copies/mL remained protective (aOR = 0.569, 95% CI: 0.329-0.984), while primary education or lower was a risk factor (aOR = 2.052, 95%CI: 1.014-4.194). Conclusion: VL levels during LLV and baseline VL predict VF risk, emphasizing the need for vigilant VL monitoring and adherence support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.